Park Avenue Securities’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Park Avenue Securities’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$942K	Buy	+14,734	New	+$764K	0.01%	981

Other funds holding KNSA

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

LTAS

Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return

FEG

Financial Enhancement Group Anderson, Indiana $839M AUM 18.63% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

JWS

Juncture Wealth Strategies Scottsdale, Arizona $384M AUM 27.62% 1-Year Est. Return

AAM

AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Park Avenue Securities's KNSA Position: Q2 2026 in Review

Park Avenue Securities opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q2 2026: 14,734 shares worth $942K. The stake represents 0.01% of the portfolio and ranks #981 among its holdings.

25 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

Park Avenue Securities held 14,734 shares of Kiniksa Pharmaceuticals worth $942K as of Q2 2026.
Kiniksa Pharmaceuticals was a new Park Avenue Securities position in Q2 2026.
Kiniksa Pharmaceuticals made up 0.01% of Park Avenue Securities's portfolio in Q2 2026, its #981 holding.
25 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.